BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi H, Zuo Y, Navaz S, Harbaugh A, Hoy C, Gandhi AA, Sule G, Yalavarthi S, Gockman K, Madison JA, Wang J, Zuo M, Shi Y, Maile MD, Knight JS, Kanthi Y. Endothelial cell-activating antibodies in COVID-19. medRxiv 2021:2021. [PMID: 33501469 DOI: 10.1101/2021.01.18.21250041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2021;59:5-30. [DOI: 10.47360/1995-4484-2021-5-30] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 14.0] [Reference Citation Analysis]
2 Wang X, Gkrouzman E, Andrade DCO, Andreoli L, Barbhaiya M, Belmont HM, Branch DW, de Jesús GR, Efthymiou M, Ríos-Garcés R, Gerosa M, El Hasbani G, Knight J, Meroni PL, Pazzola G, Petri M, Rand J, Salmon J, Tektonidou M, Tincani A, Uthman IW, Zuily S, Zuo Y, Lockshin M, Cohen H, Erkan D; APS ACTION. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus 2021;:9612033211062523. [PMID: 34915764 DOI: 10.1177/09612033211062523] [Reference Citation Analysis]
3 Foret T, Dufrost V, Salomon Du Mont L, Costa P, Lefevre B, Lacolley P, Regnault V, Zuily S, Wahl D. Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders? Curr Rheumatol Rep 2021;23:65. [PMID: 34218350 DOI: 10.1007/s11926-021-01029-3] [Reference Citation Analysis]